5,6-Diphenyl triazine-thio methyl triazole hybrid as a new Alzheimer’s disease modifying agents

2019 ◽  
Vol 24 (3) ◽  
pp. 641-654 ◽  
Author(s):  
Mahnaz Yazdani ◽  
Najmeh Edraki ◽  
Rashid Badri ◽  
Mehdi Khoshneviszadeh ◽  
Aida Iraji ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Disease Modifying ◽  
Disease Modifying Agents

scholarly journals P2-298: Assessing the economic value of potential disease-modifying agents in Alzheimer's disease using simulation

2013 ◽  
Vol 9 ◽  
pp. P467-P467
Author(s):  
Denis Getsios ◽  
Shien Guo ◽  
Nikhil Revankar ◽  
Linus Jonsson ◽  
Peter Neumann ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Economic Value ◽  
Disease Modifying ◽  
Disease Modifying Agents

Taking the Next Steps in the Treatment of Alzheimer's Disease: Disease-Modifying Agents

CNS Spectrums ◽  
2008 ◽  
Vol 13 (S3) ◽  
pp. 11-14
Author(s):  
Stephen Salloway
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Neurodegenerative Disorder ◽  
Disease Process ◽  
The United States ◽  
Disease Modification ◽  
Disease Modifying ◽  
New Treatment ◽  
Disease Modifying Agents ◽  
Disease Modifying Treatment

Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder in the United States and the number of AD patients is increasing at an alarming rate. There is no cure for AD and the currently available treatments are symptomatic, providing only limited effects on disease pathophysiology and progression. An overwhelming need exists for therapies that can slow or halt this debilitating disease process. Disease modification in AD has been defined from patient-focused, regulatory, and neurobiological perspectives. The latter two of these perspectives rely largely on an interruption of the disease process and a clear demonstration of this interruption. As defined by Cummings, a disease-modifying treatment is a “pharmacologic treatment that retards the underlying process of AD by intervening in the neurobiological processes that constitute the pathology and pathophysiology of the disease and lead to cell death or dysfunction.” By this definition, the burden of confirmatory study is placed on any new treatment for which the claim of “disease modification” is to be made (Slide 1).

scholarly journals Alzheimer‘s disease: exploring nature’s ‘medicinal chest’ for new therapeutic agents

2020 ◽  
Vol 11 (1) ◽  
pp. 201-208
Author(s):  
Anthony Tsarbopoulos
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Natural Products ◽  
Medicinal Plants ◽  
Therapeutic Agents ◽  
Lead Compounds ◽  
Age Related ◽  
Aging Properties ◽  
Disease Modifying ◽  
Disease Modifying Agents

AbstractNatural products have served humanity as a valuable source for the discovery and development of therapeutic agents. In addition, these phytochemicals can function as lead compounds for the development of synthetic analogs aimed at treating human diseases. In our aging society, Alzheimer’s disease (AD) is the most common cause of dementia, which is characterized by a significant and progressive loss of memory and other cognitive functions. As society demographics change, the predominance of AD and other age-related dementias is increasing, with concurrent financial and societal costs.AD represents one of the most remarkable scientific challenges for drug discovery as the search for effective disease-modifying agents has been unsuccessful. Medicinal plants have been used for their “anti-aging” properties, and cognitive enhancing properties. In the past decades, natural products have been studied for their anti-AD properties, and their potential for developing therapeutic agents against several molecular targets has been evaluated. This insight evaluates the prospects of medicinal plants for providing disease-modifying, as well as disease-preventing, agents for AD.

2-Arylbenzofuran-based molecules as multipotent Alzheimer's disease modifying agents

2012 ◽  
Vol 58 ◽  
pp. 519-532 ◽  
Author(s):  
Stefano Rizzo ◽  
Andrea Tarozzi ◽  
Manuela Bartolini ◽  
Gregory Da Costa ◽  
Alessandra Bisi ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Disease Modifying ◽  
Disease Modifying Agents

scholarly journals Treatment of Moderate to Severe Alzheimer's Disease: Rationale and Trial Design

2007 ◽  
Vol 34 (S1) ◽  
pp. S103-S108 ◽  
Author(s):  
Nathan Herrmann
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Nmda Receptor ◽  
Caregiver Burden ◽  
Trial Design ◽  
Cholinesterase Inhibitors ◽  
Nmda Receptor Antagonist ◽  
Disease Modifying ◽  
Disease Modifying Agents ◽  
Complete Dependence

Moderate to severe Alzheimer's disease (AD) is characterized by increasing cognitive, functional, and behavioural dysfunction that results in increased caregiver burden and, eventually, complete dependence. Despite its significance as a societal health problem, there are few treatment trials of cognitive enhancers or disease modifying agents for this stage of illness. Studies suggest the cholinesterase inhibitors, especially donepezil, may provide benefit. Several studies provide support for the use of the NMDA receptor antagonist memantine as monotherapy or added to a cholinesterase inhibitor for moderate to severe AD. While there are no published guidelines for the treatment of moderate to severe AD, these studies do provide guidance for recommendations for study design and outcome measures. Such studies are urgently needed.

scholarly journals Designing clinical trials to test disease-modifying agents: application to the treatment trials of Alzheimer’s disease

2011 ◽  
Vol 8 (1) ◽  
pp. 15-26 ◽  
Author(s):  
Chengjie Xiong ◽  
Gerald van Belle ◽  
J Philip Miller ◽  
John C Morris
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Clinical Trials ◽  
Treatment Trials ◽  
Disease Modifying ◽  
Disease Modifying Agents

M1 Muscarinic Agonists as Potential Disease-Modifying Agents in Alzheimer's Disease: Rationale and Perspectives

2006 ◽  
Vol 920 (1) ◽  
pp. 315-320 ◽  
Author(s):  
A. FISHER ◽  
D.M. MICHAELSON ◽  
R. BRANDEIS ◽  
R. HARING ◽  
S. CHAPMAN ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Muscarinic Agonists ◽  
Disease Modifying ◽  
Disease Modifying Agents ◽  
M1 Muscarinic
Sign in / Sign up

Export Citation Format

Share Document